As domestic startup is imminent to introduce new breast cancer drug from overseas, Geo-Young is in charge of third-party logistics of the drug, drawing attention. This is because it is different from the existing anticancer drug distribution method that foreign pharmaceutical companies and large domestic pharmaceutical companies used to supply.

According to the MFDS on the 27th, the screening of Nerlynx (Neratinib), a treatment for adult patients with early breast cancer positive for HER2, will be completed, and the final approval will be decided soon. It is introduced by Bixink, a subsidiary of KOSDAQ-listed company KPS, which focuses on OLED business, from Puma Biotech, Inc. in the U.S.